NASDAQ$MIRM
Mirum Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Mirum Pharmaceuticals reported financial results for the third quarter of 2021 and provided a business update.
Mirum Pharmaceuticals reported licensing revenue of $5.0 million for the quarter ended September 30, 2021, and a net loss of $47.1 million, or $1.55 per share. The company's cash, cash equivalents, and short-term investments totaled $205.0 million as of September 30, 2021. The FDA approval and launch of LIVMARLI capped a transformational third quarter for Mirum.
- U.S. commercial launch underway following U.S. FDA approval of LIVMARLI (maralixibat) oral solution
- Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort presented at AASLD.
- The Lancet published data from the pivotal LIVMARLI ICONIC study demonstrating significant and durable responses in pruritus and other clinically meaningful improvements in patients with ALGS
- Mirum will host a conference call today, November 15, 2021 at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates and discuss data presented today at AASLD.
Headline financials
Revenue & EPS history
Mirum Pharmaceuticals · Revenue · Quarterly
$5M
Revenue by segment
Mirum Pharmaceuticals · $29.1M total across 1 segment · Q1 2023
- Net Product Sales$29.1M—100.0%
Forward guidance
Mirum anticipates several milestones including Phase 3 MARCH-PFIC topline data expected in the second quarter of 2022, potential EMA approval of LIVMARLI for cholestatic liver disease in patients with ALGS in second half of 2022, and interim analyses expected in 2022 for the Phase 2b OHANA study for ICP and Phase 2b VISTAS study for PSC.
Tailwinds
- Phase 3 MARCH-PFIC topline data expected in the second quarter of 2022.
- Potential EMA approval of LIVMARLI for cholestatic liver disease in patients with ALGS in second half of 2022
- Phase 2b EMBARK study for biliary atresia enrolling; topline data expected in 2023.
- Interim analyses expected in 2022 for the Phase 2b OHANA study for ICP
- Interim analyses expected in 2022 for the Phase 2b VISTAS study for PSC
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+2.9%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+26.4%
Q2 2022
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.2% | -11.7% | |
| Q4 2025 | -15.1% | -19.2% | -18.6% | |
| Q3 2025 | -1.4% | -1.8% | -3.5% | |
| Q1 2025 | +9.9% | +9.8% | +12.5% | |
| Q4 2024 | -7.0% | -10.5% | -9.0% | |
| Q3 2024 | +5.6% | +6.9% | +1.6% | |
| Q2 2024 | +1.8% | +14.3% | +5.0% | |
| Q1 2024 | -0.3% | -4.4% | -3.2% | |
| Q4 2023 | -3.0% | -3.1% | -15.2% | |
| Q3 2023 | +5.6% | +5.6% | +12.6% | |
| Q2 2023 | +6.1% | +2.1% | +6.1% | |
| Q1 2023 | -8.3% | -7.9% | -7.9% | |
| Q4 2022 | -1.1% | -4.7% | +5.1% | |
| Q3 2022 | -16.2% | -19.7% | -24.1% | |
| Q2 2022 | +26.4% | +18.0% | +7.4% | |
| Q1 2022 | +7.1% | -4.4% | +7.0% | |
| Q4 2021 | +3.3% | +1.5% | +29.5% | |
| Q3 2021 | +0.1% | -1.2% | -7.9% | |
| Q2 2021 | +0.5% | -4.0% | +23.0% | |
| Q1 2021 | -1.4% | -6.3% | -10.8% | |
| Q4 2020 | +6.0% | +14.3% | +10.2% | |
| Q3 2020 | +11.6% | +16.9% | +48.0% | |
| Q2 2020 | +13.0% | +15.3% | -4.3% | |
| Q1 2020 | +0.1% | +6.2% | +10.8% | |
| Q4 2019 | +8.1% | -10.5% | +25.7% | |
| Q3 2019 | -0.1% | +4.0% | +22.6% | |
| Q2 2019 | -9.0% | -10.3% | -31.5% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro